Bavituximab Biosimilar - Research Grade

Human

phosphatidylserine [Homo sapiens]

>1mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This product is a research-grade biosimilar of bavituximab, supplied as an unconjugated, non-therapeutic analog of the originator molecule and intended strictly for research use. It is a chimeric human IgG1, kappa antibody that binds phosphatidylserine, a phospholipid, when presented in complex with the serum cofactor beta-2-glycoprotein I. Unlike conventional antibodies raised against a single protein epitope, bavituximab recognises an anionic membrane lipid, which is why no UniProt protein accession applies here; this is expected for a lipid-directed reagent rather than a data gap. It is built around the phosphatidylserine target and is offered for functional and in-vitro applications such as binding characterisation, membrane and apoptotic-cell recognition assays, immune-modulation studies, and use as an isotype-matched reference or positive control. The material is manufactured to research-grade specifications with low endotoxin and is available in bulk (mg to gram) quantities suitable for in-vivo standardisation and assay development. It is not a clinical drug and is not intended for diagnostic or therapeutic use. All performance parameters should be confirmed by the end user for the specific assay system. Phosphatidylserine (PS) is an anionic aminophospholipid normally confined to the inner leaflet of the plasma membrane by ATP-dependent flippases. During apoptosis, cellular stress, and within the tumour microenvironment, PS becomes externalised to the outer leaflet, where it serves as an "eat-me" signal for efferocytosis and as a potent immunosuppressive cue. Externalised PS on tumour cells, tumour vasculature, and PS-bearing extracellular vesicles helps dampen anti-tumour immunity by promoting regulatory and anti-inflammatory signalling. Bavituximab does not bind PS directly with high affinity; instead it recognises PS in complex with the plasma cofactor beta-2-glycoprotein I. By targeting exposed PS, such antibodies are studied for their ability to reverse the immunosuppressive membrane environment and to enhance immune-mediated responses. Because the target is a conserved lipid rather than a species-specific protein, PS recognition is not restricted to human material.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Bavituximab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Bavituximab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Bavituximab biosimilar target?

A: It is a non-therapeutic research analog of Bavituximab that binds phosphatidylserine [Homo sapiens]; for research use only.